Related Experiment Videos
Glucose and cardiovascular risk.
M Fuchs1, J B L Hoekstra, A H Mudde
1Slingeland Hospital, department of Internal Medicine, Doetinchem, The Netherlands.
The Netherlands Journal of Medicine
|October 9, 2002
Summary
New guidelines redefine abnormal glucose tolerance, classifying impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) as intermediate stages. Research indicates plasma glucose levels, even within the normal range, may be linked to cardiovascular risk.
Area of Science:
- Endocrinology
- Cardiology
- Metabolic Disorders
Background:
- The American Diabetes Association and World Health Organization have updated criteria for diabetes mellitus.
- Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) are now recognized as intermediate stages of glucose metabolism.
- The metabolic syndrome, a cluster of cardiovascular risk factors, often co-occurs with abnormal glucose tolerance.
Purpose of the Study:
- To review the redefined spectrum of abnormal glucose tolerance.
- To discuss the role of glucose levels as a cardiovascular risk factor.
- To examine the relationship between glucose levels and cardiovascular events.
Main Methods:
- Review of recent research and established guidelines.
- Analysis of diagnostic criteria for diabetes, IFG, and IGT.
- Discussion of the metabolic syndrome and its association with glucose abnormalities.
Main Results:
- Sharpened criteria for diabetes mellitus have been established.
- IFG and IGT are classified as distinct intermediate stages.
- Evidence suggests a link between plasma glucose levels, even in the normal range, and cardiovascular risk.
Conclusions:
- The redefinition of glucose tolerance provides clearer diagnostic pathways.
- The association between glucose levels and cardiovascular risk warrants further investigation.
- Understanding glucose's impact on cardiovascular events is crucial for risk assessment and management.